Charles Daley is a Respiratory physician affiliated with National Jewish Health. OpenAlex indexes 404 publications with 34,601 citations (h-index 77); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Pulmonary Disease profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1400 Jackson St
Denver, CO 802062761
Telephone
303-388-4461Provider last certified this registry record 11 Nov 2020.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Paratek Pharmaceuticals, Inc.Program year20258 payments
- Insmed, Inc.Program year202516 payments
- Mannkind CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
89.1%Macrolide Antimicrobial47.5%Azithromycin100%Part D≥11 patientsAminoglycoside Antibacterial20.8%Arikayce100%Part D<11 patients+ 1 more class in this area
Respiratory
10.9%Corticosteroid10.9%Breo Ellipta100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2006–2006 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
New England Journal of Medicine
2025 - Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases
The Lancet Infectious Diseases
2022 - Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline
European Respiratory Journal
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Donald Leung, MD
National Jewish Health
James Crapo, MD
National Jewish Health
Barry Make, MD
National Jewish Health
Jeffrey Swigris, DO
National Jewish Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”